The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to more affordable alternatives to brand-name drugs—including blockbusters ...
The agency has stepped up its campaign against drugmakers' improper listing of patents in the FDA's Orange Book, which it ...
The U.S. Federal Trade Commission (FTC) announced last week that it is, for the second time, disputing hundreds of “junk” ...
The Federal Trade Commission is challenging more than 300 patents filed with the Food and Drug Administration to protect market exclusivity for top-selling drugs. The patents cover 20 brand-name ...
U.S. Senator Bernie Sanders commended the Biden administration for its efforts to combat pharmaceutical companies’ ...
The warning letters don't specify how the drugmakers are flouting patent regulations, or what criteria the FTC uses to make that determination. The Federal Trade Commission on Tuesday challenged ...
The FTC recently announced that it has sent another round of letters disputing additional patent listings in the FDA’s Orange Book. With this latest action, the FTC has now challenged hundreds of ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window In Part 1 of this exclusive video interview, MedPage Today ...
The antitrust cop says that the more than 300 patent listings stall generic competition, keeping prices high for diabetes drugs, inhalers and more. The Federal Trade Commission is challenging ...
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for ...